A multicentre, double-blind, randomised study comparing the efficacy and safety of oral sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 or 6 additional days) with doxycycline (200 mg once daily for 7 days) in the treatment of non-gonococcal urethritis in men was conducted. The overall success rates for the three treatment groups were statistically equivalent both at the end of treatment and at the follow-up visits. For chlamydial urethritis, the rates of relapse or possible reinfection were similar in the 7-day sparfloxacin and doxycycline groups. For ureaplasmal urethritis and urethritis of unknown aetiology, the rates of relapse or possible reinfection were lower in the 7-day sparfloxacin group than in the other two treatment groups. Sparfloxacin was well tolerated. A 7-day sparfloxacin regimen appears to be a useful alternative to doxycycline for the treatment of non-gonococcal urethritis in men.
Introduction
In recent years the incidence of non-gonococcal urethritis (NGU) has increased in the Western world while that of gonorrhoea has decreased. NGU has now replaced gonorrhoea as the commonest cause of urethritis. NGU is an infection of multiple aetiology, usually characterised by scanty urethral discharge and the patient may complain only of slight dysuria or discomfort in the urethra in the morning. Diagnosis is confirmed by microscopy of a Gram-stained urethral smear showing an excess of polymorphonuclear leucocytes (PMN) of >5 per high power (x 1000) microscopic field (on average 20-40 pus cells) and by culture to exclude gonorrhoea.
Chlamydia trachomatis is the principal pathogen isolated in NGU and is associated with 30-50% of cases. Ureaplasma urealyticum is isolated less frequently and the remaining one-third of cases have no known cause. Trichomonas vaginalis, Corynebacterium genitalium, Haemophilus parainfluenzae and Candida spp. have been isolated from the male urethra as have the Group B streptococci and mycoplasmas, but their role in NGU remains uncertain. Tetracyclines and macrolides are satisfactory therapeutic agents for NGU, curing over 90% of C. trachomatis infections in patients who comply fully with a multi-dose daily treatment regimen. However, compliance with existing treatment regimens is poor and adverse effects are common. Several studies have shown ofloxacin to be effective in the treatment of NGU (Kitchen et al., 1990; Mogabgab et al., 1990) and sparfloxacin, a newly developed fluoroquinolone, has greater in-vitro activity against Chlamydia spp., U. urealyticum and Mycoplasma hominis than ofloxacin (Martin, Cammarata & Grubb, 1991) . Therefore, a study was conducted to compare the efficacy and safety of sparfloxacin relative to the standard treatment of doxycycline in men with NGU.
Methods

Trial design and treatment
This double-blind, randomised, multicentre study was carried out between January 1991 and April 1992. Twenty-six European centres were involved: the UK (276 patients, 1 centre); Sweden (306 patients, 8 centres); The Netherlands (65 patients, 3 centres); Germany (51 patients, 11 centres); and Spain (27 patients, 3 centres). The randomisation schedule was balanced in each treatment centre. Ethics Committee approval was obtained according to local regulations before initiation of the study at each centre. There were three treatment arms: sparfloxacin 200 mg on day 1 followed by 100 mg daily on days 2 and 3 and placebo on days 4-7, doxycycline 200 mg once daily for 7 days, and sparfloxacin 200 mg on day 1 followed by 100 mg daily on days 2-7.
Patients
All patients were to have a clinical diagnosis of NGU based on the progressive onset of at least one sign or symptom: urethral discharge (mucoid or mucopurulent), painful micturition, difficult urination and/or pruritus (which was defined as urethral irritation on micturition not amounting to dysuria), with microscopy showing > 5 PMNs per high power field (magnification x 1000). In addition, the absence of intracellular Gram-negative diplococci and yeasts had to be confirmed by direct examination of urethral samples.
Patients were to have voided no later than 3 or 4 h before the initial examination. Patients were excluded if they presented with a severe concomitant disorder likely to interfere with their clinical course, such as uncontrolled cardiovascular disorder, hepatic diseases, renal insufficiency, anaemia, cancer or AIDS, although HIV-positive patients could be included. Patients with a history of photosensitivity or multiple allergies, especially to quinolones or tetracycline, were excluded. No corticosteroid therapy, antacids, iron salts, anticoagulants, gastric emptying modifiers or immunosuppressants could be taken during the study period.
The number of PMNs per high power field in the urethral smear and the presence or absence of intracellular Gram-negative diplococci and yeasts by direct microscopic examination were determined before treatment (V,) and at the end-of-treatment visit (V 2 ) and at the follow-up visit (V 3 ). The general state of health was assessed at study entry by means of a full medical history (including the number of episodes of gonococcal urethritis, NGU and genital herpes in the past year) and physical examination. This was repeated at V 2 and V 3 . Patients were questioned about previous and current use of condoms at Vi and, if sexual activity had continued, at V 2 and V 3 .
Urethral samples for bacteriology were obtained at inclusion and at each visit (V 2 and V 3 ) by endourethral swab. These samples were used for culture of Neisseria gonorrhoeae, C. trachomatis, U. urealyticum and M. hominis, and for the detection of C. trachomatis antigen (e.g. immunofluorescence or ELISA tests) where possible. If TV. gonorrhoeae was isolated, susceptibility testing was performed using sparfloxacin and doxycycline discs.
Clinical evaluation
The primary efficacy analysis was based on the overall efficacy response at V 2 (days 9-12) and at V 3 (days 21-25), combining the clinical and bacteriological responses and the number of PMNs per field in the urethral smear.
In order to be eligible for the primary efficacy analysis, the patients had to comply with the following inclusion criteria: negative culture for N. gonorrhoeae at inclusion and at study entry; presence of at least one of the following-urethral discharge, painful urination, difficult urination or pruritus associated with > 5 PMNs per high power field.
Where there were no clinical signs or symptoms at inclusion, patients were deemed evaluable if the culture was positive for C. trachomatis irrespective of the number of PMNs or for U. urealyticum when associated with > 5 PMNs. In addition, there had to be no other genital infection (such as prostatitis) at entry, at least 3 complete days of treatment with study medication, a satisfactory compliance, and no discontinuation before the end of treatment unless there was treatment failure.
In order to be evaluable for the primary efficacy analysis at V 2 , the patient had to be evaluated between days 7 and 16 inclusive (if only one visit was performed after inclusion, it was considered V 2 if it took place before day 17 and V 3 if it took place on or after day 17). To be evaluable for primary efficacy at V 3 , the patient had to be evaluated on or after day 17 and could not have taken any systemic antibiotic treatment between V 2 and V 3 , except in the case of failure or relapse/reinfection. All patients who fulfilled the inclusion criteria and received at least one tablet of study medication were included in the intent-to-treat-analysis. All patients who received at least one dose of study medication were included in the safety analysis.
Criteria for assessment of outcome
Clinical cure was defined as complete disappearance of urethral discharge and painful or difficult urination. Improvement was defined as disappearance of urethral discharge with decrease or persistence of at least one other symptom.
The bacteriological response was defined as follows: eradication-disappearance of all pathogens (C. trachomatis, U. urealyticum) present at inclusion; persistence-persistence of at least one of the initial pathogens; reinfection-eradication of the initial pathogen and replacement by a new pathogen; superinfection-persistence of the initial pathogen with appearance of a new pathogen; indeterminate-no pathogen at inclusion or at each visit; appearance-appearance of a pathogen with no pathogen at inclusion; unassessable-positive culture at inclusion and culture not repeated at the endpoint visit; relapse/possible reinfection-eradication of all initial pathogens at V 2 with presence of at least one pathogen at the follow up visit (V 3 ). M. hominis was not considered to be a causative pathogen. When the patient was judged clinically 'cured', 'indeterminate' or 'improved', U. urealyticum was not considered to be a pathogen if it appeared or persisted at V 2 or V 3 .
For the primary efficacy analyses, the assessments for each visit were defined for the purpose of the statistical analysis as success or non-success (the non-successes would represent cases that would generally be interpreted by the investigators as failures irrespective of the classification used in the study) as follows: At the end-of-treatment visit (V 2 ), success-clinical cure irrespective of the number of PMNs, or clinical improvement with ^ 5 PMNs, together with the absence of C. trachomatis (whether U. ureaplasma was isolated or not); non-success-all other cases. At the follow-up visit (V 3 ), success-clinical cure with ^ 10 PMNs and always fewer than at V 2 and absence of C. trachomatis (whether U. urealyticum was isolated or not); non-success-all other cases.
When either V 2 or V 3 was missed, a patient classified as non-success at one visit was still classified as non-success in the missing visit but a patient classified as 'success' at one visit would not be evaluable at the missing visit.
Adverse events
A laboratory profile was obtained at inclusion and V 2 and, if clinically significant abnormal values were found, it was repeated at V 3 . The profile included: haematology-RBC count, haemoglobin, platelet count, total and differential WBC count, prothrombin, activated PTT and ESR; biochemistry-sodium, potassium, chloride, bicarbonate, total protein, glucose, uric acid, total bilirubin, ASAT (SGOT), ALAT (SGPT), alkaline phosphatase, creatinine, calcium, phosphate; and urinalysisprotein, blood and glucose (by dip stick).
Clinical events, whether volunteered by the patient or elicited by the investigator by non-specific questioning, were recorded at V 2 and V 3 . All were classified by the investigator with regard to severity and possible relation to study medication.
Statistical methods
All statistical analyses were carried out with SAS software, release 6.06 (SAS Institute, Gary, North Carolina, USA). The primary statistical methodology was the calculation of 90% confidence intervals for difference in success rates between the three treatment groups at V 2 and V 3 . Equivalence was accepted when the upper limit of the interval was < 10%. The probabilities excluding 10% from these intervals when treatment regimens were truly equivalent were also calculated. All other analyses were descriptive.
Results
A total of 725 patients were included in the study: 243 were randomised to the sparfloxacin-3 days group, 239 to the doxycycline-7 days group and 243 to the sparfloxacin-7 days group. Of the 725 patients randomised to the study, 42 were lost to follow-up just after inclusion and no information was available on drug intake. A further two were excluded from the intent-to-treat analysis because they had no clinical signs or symptoms and negative cultures. The number of patients included in the intent-to-treat analysis and in the primary efficacy analyses at V 2 and V 3 are presented in Table I . 
Demographic data
Patient characteristics and sexual practices were similar in the three treatment groups (Table II) . In approximately 60% of cases, symptoms of NGU had been present for more than one week before inclusion. Urethral discharge (most often mild and mucoid) was observed in approximately 80% of cases. Among the symptoms, painful urination was observed more often (60% of patients) than difficult urination (10%) or pruritus (30%). The distribution of clinical signs and symptoms was also similar in the three treatment groups. All except 24 patients had >5 PMNs per high power field in the urethral smear. Two-thirds of the patients had > 10 PMNs per high power field. 
Bacteriology
The bacteriological findings at inclusion are provided in Table III . In less than half of patients entered, no pathogens were identified in the urethral sample. Spain had the highest rate of success in identifying a pathogen (76.9%) whereas The Netherlands had the lowest rate (35.6%). The rate of isolation of C. trachomatis alone was approximately 37%, whether or not with U. urealyticum and was lowest in Spain (19.2%), which had the highest rate of isolation of U. urealyticum alone (57.7%), and highest in Sweden (41.8%). The overall success rates were statistically equivalent at V 2 and V 3 in the three treatment groups both in the intention-to-treat population and the patients evaluable for primary efficacy. The confidence interval of the difference of the success rate was always under 10% in all analyses, confirming equivalence. The individual success rates at both endpoints intention-to-treat and evaluable patients are presented in Table IV .
Overall efficacy at V 2 and V 3 according to the pathogen isolated is presented in Tables V-VII. The doxycycline regimen was slightly more effective than the two sparfloxacin regimens in the 230 evaluable patients with chlamydial urethritis, but the relapse rates at V 3 appeared equivalent in the three treatment groups (12%, 13%, 15% in the 3-day sparfloxacin, doxycycline, and 7-day sparfloxacin regimens, respectively Table V ). In contrast, the two sparfloxacin regimens were more effective than the doxycycline regimen in the 102 evaluable patients with ureaplasmal urethritis (Table VI) . Moreover, the relapse rate at V 3 (defined as a success at visit 2 and unsuccessful at visit 3) was lower in the 7-day sparfloxacin group than in the other two treatment groups (12% vs 18% in the 3-day sparfloxacin and 17% in the doxycycline group). However, the numbers involved were small. In the 276 evaluable patients with no pathogens isolated at inclusion, the 7-day sparfloxacin regimen was as effective as the doxycycline regimen but the relapse rate at V 3 was lower in the 7-day sparfloxacin The number of patients evaluable at each visit is less than the number of patients evaluable for the primary efficacy analysis (Table III) , because some patients were excluded from the analysis due to a visit date out of the admissible range, or due to the use of systemic antibiotics in spite of failure. group. The relapse rate for the 3-day sparfloxacin group was markedly higher (Table VII) . The results in the cases evaluable for bacteriological efficacy at V 2 are presented in Table VIII ; the eradication rates for C. trachomatis were close to 100% in the three groups: 3-day sparfloxacin, 7-day doxycycline and 7-day sparfloxacin groups. The eradication rates of U. urealyticum were also close to 100% in all three groups. When U. urealyticum persisted or appeared at the end of the treatment, this was rarely associated with a clinical failure (1/6, 1/5, 2/6 in the above groups, respectively).
The results in the bacteriologically evaluable cases at V 3 are presented in Table VIII ; the eradication rates for C. trachomatis were 88.1% (59/67), 96.1% (73/76) and 97.0% (64/66) in the 3-day sparfloxacin, 7-day doxycycline and 7-day sparfloxacin groups, respectively. A relapse or possible reinfection with C. trachomatis was observed in 6, 2 and 1 patient in the 3-day sparfloxacin, 7-day doxycycline and 7-day sparfloxacin groups, respectively. The eradication rates of U. urealyticum were 86.0% (43/50), 80.9% (38/47) and 77.5% (31/40) in the 3-day sparfloxacin, 7-day doxycycline and 7-day sparfloxacin groups, respectively. The eradication rates of U. urealyticum were 86.0% (43/50), 80.9% (38/47) and 77.5% (31/40) in the 3-day sparfloxacin, 7-day doxycycline and 7-day sparfloxacin groups, respectively. This organism appeared in five cases in the 3-day sparfloxacin group, five cases in the doxycycline group and nine cases in the 7-day sparfloxacin group. However, when U. urealyticum persisted, appeared or reappeared, this was rarely associated with a clinical failure (2/12, 4/14, 3/18 in the three treatment groups, respectively).
Analysis of non-successes at V 2
Of the 608 patients evaluable for overall efficacy at V 2 , 114 were classified as non-success: 36/195 (18.5%) patients who received sparfloxacin for 3 days, 38/212 (17.9%) who received doxycycline and 40/201 (19.9%) who received sparfloxacin for 7 days. Because these patients were classified as non-success at V 2 , they were subsequently classified as non-success at V 3 . Pathogens, either C. trachomatis or U. urealyticum, were isolated from 11% of the cases of non-success (Table IX) .
Analysis of relapse/reinfection
Of the 608 patients evaluable for overall efficacy at V 2 , 100 patients were classified as success at V 2 and non-success at V 3 : 36/195 (18.5%) patients in the 3-day sparfloxacin group, 36/212 (17.0%) in the doxycycline group and 28/201 (13.9%) in the 7-day sparfloxacin group. Pathogens were isolated in 16 of the cases of relapse/reinfection (Table X) .
Adverse events
Forty-two of the 725 patients were not evaluable with regard to adverse events because they were lost to follow-up just after inclusion or did not take the study medication. Thus the adverse events analysis included 683 patients (222 in the 3-day sparfloxacin group, 230 in the doxycycline group and 231 in the 7-day sparfloxacin group). Adverse events were reported by 28.4%, 37.0%, and 26.4% of the patients for the 3-day sparfloxacin, doxycycline and 7-day sparfloxacin groups, respectively. Severe adverse events were reported in few patients: none in the 3-day sparfloxacin group, 6% in the doxycycline group and 2.5% in the 7-day sparfloxacin group. Gastrointestinal disorders such as nausea, abdominal pain and diarrhoea were the most frequently reported (Table XI) , particularly in the doxycycline group. A photosensitivity reaction occurred in one patient in the 3-day sparfloxacin group, one patient in the doxycycline group, and two patients in the 7-day sparfloxacin group. These reactions were mild in intensity, always occurred after exposure to sunlight and resolved spontaneously.
No life-threatening adverse events were reported during the study. However, five patients discontinued their treatment due to adverse events: one in the 3-day sparfloxacin group (mild, generalised rash which disappeared spontaneously the day after treatment discontinuation), two in the doxycycline group (severe gastrointestinal disorder and/or moderate urticaria) and two in the 7-day sparfloxacin group (moderate urticaria 4 days after initiation of treatment and drowsiness/impaired concentration several hours after initiation of treatment).
A slight increase in mean total bilirubin, hepatic transaminases, glucose, creatinine and eosinophils and a slight decrease in mean alkaline phosphatase was noted in the two sparfloxacin groups compared to the doxycycline group. Few cases were considered to be clinically significant.
Discussion
The in-vitro anti-chlamydial activity of sparfloxacin is equivalent to that of doxycycline but superior to that of ofloxacin (Martin et al., 1991) , a fluoroquinolone shown to be effective in the treatment of NGU (Kitchen et al., 1990; Mogabgab et al., 1990) . In addition, sparfloxacin has better in-vitro activity than ofloxacin against U. urealyticum and M. hominis and is equally active against doxycycline-susceptible and -resistant strains (Renaudin & Bebear, 1992) .
In large surveys, 12% and 88% of 1,528 strains of U. urealyticum and 14% and 100% of 299 strains of M. hominis were resistant to doxycycline and erythromycin, respectively (Spaepen & Kundsin, 1966; Poulin & Kundsin, 1991) . Susceptibility of both organisms to sparfloxacin appears to be independent of resistance to doxycycline, tetracycline and erythromycin (Poulin & Kundsin, 1991) . Recently reported sparfloxacin MIC90 values are: C. trachomatis 0.1 mg/L (Martin et al., 1991) , U. urealyticum 0.5 mg/L and M. hominis 0.03 mg/L (Waites et al., 1991) .
In the present study, C. trachomatis was isolated alone in 31% of the cases, which is consistent with the C. trachomatis isolation rates of 30 to 60% reported in the literature (Alani et al., 1977; Oriel & Ridgway, 1982; Mardh, Paavonen & Puolakkainen, 1989 ) and both C. trachomatis and U. urealyticum were isolated in 7% of cases. Evidence implicating U. urealyticum in NGU remains controversial (Taylor-Robinson, Czonka & Prentice, 1977; Matsuda, Takeuchi & Yoshida, 1991) .
Clearly, U. urealyticum can be implicated as a cause of urethritis in a minority of patients in whom the organism is isolated (Taylor-Robinson & McCormack, 1980; Taylor-Robinson, 1983; Woolley, 1990) . Pathogen-negative NGU is less likely to respond to conventional therapy with tetracycline or erythromycin and relapse is more likely (Handsfield et al., 1976) . This suggests either an as yet unidentified micro-organism, less responsive to standard NGU therapy, or a non-infective inflammatory process. Because it is uncertain whether M. hominis is a pathogen in NGU, it was not considered an infecting organism in this study.
The overall success rates at the end-of-treatment and the final visit were statistically equivalent in each of the treatment groups. However, when subpopulations with ureaplasmal urethritis and urethritis of unknown aetiology were examined, it was found that the rates of relapse/possible reinfection at the follow-up visits were markedly lower in the 7-day sparfloxacin group compared with the other two treatment groups. However, the rates of relapse/possible reinfection for chlamydial urethritis were similar in all three treatment groups. The eradication rates for C. trachomatis were in excess of 95% in all groups at end of treatment and at follow-up except in the 3-day sparfloxacin group at follow-up. The eradication rate of U. urealyticum was less than 95% in all groups at end of treatment; they were 86%, 80.9% and 77.5% in the 3-day sparfloxacin group, doxycycline group and 7-day sparfloxacin group respectively; however, when this pathogen persisted, appeared or re-appeared at follow-up this was rarely associated with a clinical failure.
The three treatment regimens were well tolerated. Adverse events were rarely severe enough to necessitate discontinuation of treatment. Gastrointestinal adverse events were the most frequently reported, particularly in patients treated with doxycycline. In summary, a 7-day course of sparfloxacin was equally as effective as a 7-day course of doxycycline and was associated with a lower rate of relapse/possible reinfection in patients with ureaplasmal urethritis and urethritis of unknown aetiology. Sparfloxacin also has good in-vitro activity against C. trachomatis and is well tolerated and therefore should prove to be a useful alternative treatment for NGU in men.
